Drug Profile


Alternative Names: Nazasetron; Serotone; Y 25130

Latest Information Update: 20 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Japan Tobacco; Mitsubishi Pharma Corporation; Mitsubishi Tanabe Pharma Corporation; Taiho Pharmaceutical; Torii Pharmaceutical; University of California at San Francisco
  • Class Antiemetics; Antineoplastics; Heterocyclic bicyclo compounds; Oxazines
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Nausea and vomiting
  • Discontinued Cocaine abuse; Gastrointestinal disorders

Most Recent Events

  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
  • 08 May 2007 Discontinued - Preclinical for Cocaine abuse in USA (unspecified route)
  • 16 May 2002 Discontinued - Phase-II for Gastrointestinal disorders in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top